A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification

ᅟ: The overall purpose of this study is to provide proof of concept for introducing the anthracycline epirubicin as an effective, biomarker-guided treatment for metastatic colorectal cancer (mCRC) patients who are refractory to treatment with oxaliplatin-based chemotherapy and have TOP2A gene amplif...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarpgaard, Line S., Qvortrup, Camilla, Nygård, Sune B., Nielsen, Signe L., Andersen, Diana R., Jensen, Niels Frank, Stenvang, Jan, Detlefsen, Sönke, Brünner, Nils, Pfeiffer, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750171/
https://www.ncbi.nlm.nih.gov/pubmed/26867764
http://dx.doi.org/10.1186/s12885-016-2124-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750171/
https://www.ncbi.nlm.nih.gov/pubmed/26867764
http://dx.doi.org/10.1186/s12885-016-2124-5

Ejemplares similares